Notable Stock to Watch: Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB)

Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) changed -0.79% to recent value of $22.56. The stock transacted 115573 shares during most recent day however it has an average volume of 172.18K shares. It spotted trading -27.23% off 52-week high price. On the other end, the stock has been noted 48.71% away from the low price over the last 52-weeks.

Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that it has completed a successful Type B Pre-Biologics License Application (“Pre-BLA”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential pathway for FDA approval of naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

At the meeting, the Company reached alignment with the FDA on an Accelerated Approval Pathway for naxitamab along with a rolling BLA submission. The Company expects to submit the Clinical/Safety portion and the non-Clinical portion of the BLA in November 2019. For the CMC portion, the Company believes it will have sufficient data from the process performance qualification (“PPQ”) batches to complete the CMC portion in early 2020. However, Y-mAbs is still investigating possibilities for accelerating the submission of the CMC portion, and hope to comply with the FDA requirements at an earlier time.

Under naxitamab’s breakthrough therapy designation (“BTD”), the compound qualifies for a Rolling BLA, which enables individual modules of the application to be submitted by the Company and reviewed by the FDA on a rolling basis, rather than waiting for all sections to be completed before submission. The rolling application process will provide the Company with the opportunity for ongoing communications with the FDA, and, during this rolling process, the Company anticipates that it will be able to address any substantial matters raised by the FDA.

Based on the previously announced efficacy data from Study 12-230 in relapsed/refractory high-risk neuroblastoma patients at Memorial Sloan Kettering Cancer Center (“MSK”), the FDA determined that efficacy data from all 37 patients of the Company’s multicenter Study 201 would not be required for the BLA filing. The FDA advised the Company that the available data for the first group of patients treated outside MSK in Study 201 would be sufficient for the BLA filing. The first group consists of 24 patients, of which 11 were evaluable prior to the pre-BLA meeting and showed an overall response rate (“ORR”) of 73%, including 55% complete responses (“CR”), as assessed by the investigators. The Company intends to announce the complete dataset for Study 201 once the data becomes available.

“The positive outcome of the Pre-BLA meeting will be consequential for high-risk neuroblastoma patients waiting to get access to this new outpatient treatment with encouraging data,” stated Thomas Gad, Founder, Chairman, President and Head of Business Development and Strategy.

Dr. Claus Moller, Chief Executive Officer, continued, “We are pleased to see that the clinical data previously generated at MSK was able to be replicated at other sites. We believe that an ORR of 73% may place naxitamab in a strong position in the market for the treatment of high-risk neuroblastoma.”

 YMAB . Its earnings per share (EPS) expected to touch remained -156.10% for this year .

 The company has 33.3M of outstanding shares and 16.68M shares were floated in the market. According to the most recent quarter its current ratio was 13.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of 1.89% from the mean of 20 days, 3.11% from mean of 50 days SMA and performed -0.67% from mean of 200 days price. Company’s performance for the week was -1.36%, 7.12% for month and YTD performance remained 10.91%.

Leave a Reply

Your email address will not be published. Required fields are marked *